Login | Register

Brentuximab vedotin shows extended survival in HL and sALCL

Updated 3-year results for two brentuximab vedotin (Adcetris™) pivotal phase II trials in patients with relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma both showed extended survival for these heavily pre-treated patients. The studies were presented at the 55th American Society of Hematology meeting, held in New Orleans, LA, December 7-10, 2013.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *